走向硬性停药?每周托珠单抗停用后逐渐减量托珠单抗对巨细胞动脉炎的影响:一项多中心评估
该研究为英国多中心服务评估的二次分析,纳入40个中心336例巨细胞动脉炎患者,比较每周托珠单抗停用后逐渐减量(17.0%,57/336)与直接停药患者的复发时间。在充分应答者中,减量期间复发时间显著长于非减量组(P=0.0231),但减量结束后两组无差异(P=0.8346);非充分应答者中减量与否无差异(P=0.4892)。
要点
- 充分应答者停用每周托珠单抗后复发时间显著长于非充分应答者(P=0.0004)。
- 充分应答者减量期间复发时间显著长于非减量组(P=0.0231),基于相对较少的复发例数。
- 减量结束后减量组与非减量组复发时间无差异(P=0.8346)。
核心结论
- 每周托珠单抗停用后逐渐减量仅在减量期间延迟复发,且仅见于对每周托珠单抗充分应答者;减量结束后未见持久获益。
研究设计与样本
- 英国多中心服务评估的二次分析,评估巨细胞动脉炎患者停用每周托珠单抗后的复发情况,比较减量组与非减量组至复发时间,共分析40个中心的336例患者。
主要发现
- 充分应答者停用每周托珠单抗后至复发时间显著长于非充分应答者(P=0.0004)。
- 17.0%(57/336)患者在停用每周托珠单抗后减量至每两周托珠单抗,中位减量时长6个月(IQR 2-13)。
- 充分应答者中,减量期间至复发时间显著长于非减量组(P=0.0231),该分析基于相对较少的复发例数。
- 减量组与非减量组在减量托珠单抗停止后至复发时间无差异(P=0.8346)。
- 非充分应答者中,减量组与非减量组至复发时间相似(P=0.4892)。
关键数值与推荐
- 充分应答者定义为停用每周托珠单抗时处于缓解且泼尼松龙剂量≤5 mg、且在每周托珠单抗治疗期间无复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In England, there is a 'hard stop' to weekly tocilizumab (qwTCZ) therapy for GCA; this is currently 12 months but was extended during the COVID-19 pandemic subject to certain criteria for GCA relapse risk. Taking advantage of variation in practice, we aimed to compare outcomes of GCA patients who tapered-TCZ vs those who stopped abruptly (non-taper patients). METHODS: Secondary analysis of an English multicentre service evaluation of relapse after stopping qwTCZ for GCA. Time to relapse was compared between taper and non-taper patients. We examined outcomes according to whether they had been 'adequate responders' during qwTCZ therapy, defined as those in remission and on ≤5 mg prednisolone at qwTCZ cessation, without relapse whilst taking qwTCZ. RESULTS: We analysed 336 patients from 40 centres. Time to relapse after qwTCZ cessation was significantly longer in adequate responders than non-adequate responders (P = 0.0004). 17.0% (57/336) patients tapered to fortnightly TCZ after qwTCZ cessation, for a median of 6 (IQR 2-13) months. For adequate responders, time to relapse whilst taking tapered-dose TCZ was significantly longer compared with those in the non-taper group (P = 0.0231) based on a relatively small number of flares. There was no difference between the taper and non-tapered groups after tapered-TCZ was stopped (P = 0.8346). In contrast, time to relapse for non-adequate responders was similar in taper patients compared with non-taper patients (P = 0.4892). CONCLUSION: Tapering TCZ after qwTCZ cessation delayed relapse only during the tapering period, but only in adequate responders to qwTCZ. No lasting benefit was seen after tapering ended.
引用
- Quick V, Sah S, Dubey S, et al. Coming to a hard stop? Effect of tapered tocilizumab after weekly tocilizumab cessation for GCA: a multicentre evaluation. Rheumatology (Oxford). 2026. PMID: 40857555. doi:10.1093/rheumatology/keaf450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。